Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Gynther

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Pharmaceutics|February 25, 2023
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and TherapyElena Puris, Gert Fricker, Mikko Gynther
Pharmaceutical Research|April 1, 2022
Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?Elena Puris, Gert Fricker, Mikko Gynther
International Journal of Pharmaceutics|August 28, 2018
Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agentsJohanna Huttunen, Mikko Gynther, Kristiina M Huttunen
The AAPS Journal|May 1, 2008
Prodrug approaches for CNS deliveryJarkko Rautio, Krista Laine, Mikko Gynther, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 12, 2014
Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1)Jarkko Rautio, Jussi Kärkkäinen, Kristiina M Huttunen, et al.
Pharmaceutical Research|May 8, 2020
L-Type amino acid transporter 1 as a target for drug deliveryElena Puris, Mikko Gynther, Seppo Auriola, et al.
Pharmaceutics|April 16, 2020
L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin LevelsAhmed Montaser, Marko Lehtonen, Mikko Gynther, et al.
International Journal of Pharmaceutics|October 15, 2019
L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs)Johanna Huttunen, Mikko Gynther, Kati-Sisko Vellonen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 1, 2017
L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugsElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 10, 2019
L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain deliveryElena Puris, Mikko Gynther, Johanna Huttunen, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Pharmaceutics|February 25, 2023
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and TherapyElena Puris, Gert Fricker, Mikko Gynther
Pharmaceutical Research|April 1, 2022
Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?Elena Puris, Gert Fricker, Mikko Gynther
International Journal of Pharmaceutics|August 28, 2018
Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agentsJohanna Huttunen, Mikko Gynther, Kristiina M Huttunen
The AAPS Journal|May 1, 2008
Prodrug approaches for CNS deliveryJarkko Rautio, Krista Laine, Mikko Gynther, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 12, 2014
Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1)Jarkko Rautio, Jussi Kärkkäinen, Kristiina M Huttunen, et al.
Pharmaceutical Research|May 8, 2020
L-Type amino acid transporter 1 as a target for drug deliveryElena Puris, Mikko Gynther, Seppo Auriola, et al.
Pharmaceutics|April 16, 2020
L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin LevelsAhmed Montaser, Marko Lehtonen, Mikko Gynther, et al.
International Journal of Pharmaceutics|October 15, 2019
L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs)Johanna Huttunen, Mikko Gynther, Kati-Sisko Vellonen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 1, 2017
L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugsElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 10, 2019
L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain deliveryElena Puris, Mikko Gynther, Johanna Huttunen, et al.
Pageof 6